Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2014

Open Access 01-12-2014 | Research article

A novel systems pharmacology model for herbal medicine injection: a case using reduning injection

Authors: Haixing Yang, Wenjuan Zhang, Chao Huang, Wei Zhou, Yao Yao, Zhenzhong Wang, Yan Li, Wei Xiao, Yonghua Wang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Login to get access

Abstract

Background

Compared with the traditional oral administration form, injection administration is basically superior in terms of both biological availability and therapeutic effects. However, few researches have focused on the traditional Chinese medicinal injection due to the complicated constituents and the intricate mechanism of action.

Methods

In the present work, a novel systems pharmacology model, integrating ADME (absorption, distribution, metabolism, and excretion) filtering such as half-life evaluation, network targeting, pathway and systems analyses, is specifically developed for the identification of active compounds and the study of the mechanism of action of TCM injection, which is exemplified by Reduning injection confronting the influenza.

Results

The ADME filter successfully identifies 35 bioactive compounds (31 molecules and 4 metabolites) from the Reduning injection. The systems analysis and experimental validation further reveal a new way of confronting influenza disease of this injection: 1) stimulating the immunomodulatory agents for immune response activation, and 2) regulating the inflammatory agents for anti-inflammation.

Conclusions

The novel systems pharmacology method used in this study has the potential to advance the understanding of the molecular mechanisms of action of multicomponent herbal injections, and provide clues to discovering more effective drugs against complex diseases.
Appendix
Available only for authorised users
Literature
1.
Zhou G, Chen S, Wang Z, Chen Z: Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res. 2007, 17 (4): 274-276. 10.1038/cr.2007.21.CrossRefPubMed
2.
Xu H, Wang Y, Liu N: Safety of an injection with a mixture of extracts from Herba Artemisiae annuae, Fructus Gardeniae and Flos Lonicerae. Pharm World Sci. 2009, 31 (4): 458-463. 10.1007/s11096-009-9297-9.CrossRefPubMed
3.
Zhang A, Sun H, Wang Z, Sun W, Wang P, Wang X: Metabolomics: towards understanding traditional Chinese medicine. Planta Med. 2010, 76 (17): 2026-2035. 10.1055/s-0030-1250542.CrossRefPubMed
4.
Quintana-Murci L, Chaix R, Wells RS, Behar DM, Sayar H, Scozzari R, Rengo C, Al-Zahery N, Semino O, Santachiara-Benerecetti AS: Where west meets east: the complex mtDNA landscape of the southwest and central Asian corridor. Am J Hum Genet. 2004, 74 (5): 827-845. 10.1086/383236.CrossRefPubMedPubMedCentral
5.
van der Graaf P, Benson N: Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011, 28 (7): 1460-1464. 10.1007/s11095-011-0467-9.CrossRefPubMed
6.
Zhao S, Iyengar R: Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012, 52: 505-521. 10.1146/annurev-pharmtox-010611-134520.CrossRefPubMedPubMedCentral
7.
Li P, Chen J, Wang J, Zhou W, Wang X, Li B, Tao W, Wang W, Wang Y, Yang L: Systems pharmacology strategies for drug discovery and combination with applications to CVD. J Ethnopharmacol. 2013, 151 (1): 93-107.CrossRefPubMed
8.
Tao W, Xu X, Wang X, Li B, Wang Y, Li Y, Yang L: Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2012, 145: 1-10.CrossRefPubMed
9.
Huang C, Zheng C, Li Y, Wang Y, Lu A, Yang L: Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform. 2013, 15 (5): 710-733.CrossRefPubMed
10.
Li B, Xu X, Wang X, Yu H, Li X, Tao W, Wang Y, Yang L: A systems biology approach to understanding the mechanisms of action of Chinese herbs for treatment of cardiovascular disease. Int J Mol Sci. 2012, 13 (10): 13501-13520.CrossRefPubMedPubMedCentral
11.
Liu H, Wang J, Zhou W, Wang Y, Yang L: Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol. 2013, 52: 773-793.CrossRef
12.
Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L: Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-Huang decoction. J Ethnopharmacol. 2013, 150 (2): 619-638. 10.1016/j.jep.2013.09.018.CrossRefPubMed
13.
Wang X, Xu X, Tao W, Li Y, Wang Y, Yang L: A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. Evid Based Complement Altern Med. 2012, 2012:
14.
Li Y, Wang Z, Bi Y, Ding G, Sheng L, Qin J, Xiao W, Li J, Wang Y, Wang X: The evaluation and implementation of direct analysis in real time quadrupole time-of-flight tandem mass spectrometry for characterization and quantification of geniposide in Re Du Ning injections. Rapid Commun Mass Spectrom. 2012, 26 (11): 1377-1384. 10.1002/rcm.6235.CrossRefPubMed
15.
Li H: Study on the Therapeutical Basis of Composite Herbal Medicines of Reduning Injection. 2013, Accepted
16.
van de Waterbeemd H, Gifford E: ADMET in silico modelling: towards prediction paradise?. Nat Rev Drug Discov. 2003, 2 (3): 192-204. 10.1038/nrd1032.CrossRefPubMed
17.
Tetko I, Tanchuk V, Villa A: Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci. 2001, 41 (5): 1407-1421. 10.1021/ci010368v.CrossRefPubMed
18.
Lipinski C, Lombardo F, Dominy B, Feeney P: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012, 46: 3-26.CrossRef
19.
Sun H: A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J Chem Inf Comput Sci. 2004, 44 (2): 748-757. 10.1021/ci030304f.CrossRefPubMed
20.
Jorgensen W, Duffy E: Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002, 54 (3): 355-366. 10.1016/S0169-409X(02)00008-X.CrossRefPubMed
21.
Lin J, Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003, 42 (1): 59-98. 10.2165/00003088-200342010-00003.CrossRefPubMed
22.
Wang Y, Li Y, Yang S, Yang L: Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model. 2005, 45 (3): 750-757. 10.1021/ci050041k.CrossRefPubMed
23.
Kratochwil N, Huber W, Müller F, Kansy M, Gerber P: Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002, 64 (9): 1355-1374. 10.1016/S0006-2952(02)01074-2.CrossRefPubMed
24.
Zsila F, Bikadi Z, Malik D, Hari P, Pechan I, Berces A, Hazai E: Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking. Bioinformatics (Oxford, England). 2011, 27 (13): 1806-1813. 10.1093/bioinformatics/btr284.CrossRef
25.
Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D, Waterman M, Gotoh O, Coon M, Estabrook R: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996, 6 (1): 1-51. 10.1097/00008571-199602000-00002.CrossRefPubMed
26.
Saunders KC: Automation and robotics in ADME screening. Drug Discov Today Technol. 2004, 1 (4): 373-380. 10.1016/j.ddtec.2004.11.009.CrossRefPubMed
27.
Rostkowski M, Spjuth O, Rydberg P: WhichCyp: prediction of cytochromes P450 inhibition. Bioinformatics (Oxford, England). 2013, 29: 2051-2052. 10.1093/bioinformatics/btt325.CrossRef
28.
Manga N, Duffy J, Rowe P, Cronin M: Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005, 16 (1–2): 43-61.CrossRefPubMed
29.
Madden JC: In Silico Approaches for Predicting ADME Properties. Recent Advances in QSAR Studies. 2010, Netherlands: Springer, 283-304.CrossRef
30.
Kidron H, Del Amo EM, Vellonen KS, Urtti A: Prediction of the vitreal half-life of small molecular drug-like compounds. Pharm Res. 2012, 29 (12): 3302-3311. 10.1007/s11095-012-0822-5.CrossRefPubMed
31.
Boulesteix A-L: PLS dimension reduction for classification with microarray data. Stat Appl Genet Mol Biol. 2004, 3 (1): Article 33-
32.
Chung D, Keles S: Sparse partial least squares classification for high dimensional data. Stat Appl Genet Mol Biol. 2010, 9 (1): Article 17-
33.
Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V: DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs. Nucleic Acids Res. 2011, 39 (Database issue): D1035-D1041.CrossRefPubMed
34.
Todeschini R, Consonni V: Handbook of Molecular Descriptors. 2008, Wiley.com
35.
Walters W, Murcko M: Prediction of ‘drug-likeness’. Adv Drug Deliv Rev. 2002, 54 (3): 255-271. 10.1016/S0169-409X(02)00003-0.CrossRefPubMed
36.
Ma C, Wang L, Xie X-Q: GPU accelerated chemical similarity calculation for compound library comparison. J Chem Inf Model. 2011, 51 (7): 1521-1527. 10.1021/ci1004948.CrossRefPubMedPubMedCentral
37.
Rix U, Superti-Furga G: Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009, 5 (9): 616-624. 10.1038/nchembio.216.CrossRefPubMed
38.
Yu H, Chen J, Xu X, Li Y, Zhao H, Fang Y, Li X, Zhou W, Wang W, Wang Y: A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One. 2012, 7 (5): e37608-10.1371/journal.pone.0037608.CrossRefPubMedPubMedCentral
39.
Keiser M, Roth B, Armbruster B, Ernsberger P, Irwin J, Shoichet B: Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007, 25 (2): 197-206. 10.1038/nbt1284.CrossRefPubMed
40.
Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, Bork P: STITCH 3: zooming in on protein–chemical interactions. Nucleic Acids Res. 2012, 40 (D1): D876-D880. 10.1093/nar/gkr1011.CrossRefPubMed
41.
Xu Q, Qu F, Pelkonen O: Network Pharmacology and Traditional Chinese Medicine. 2012CrossRef
42.
Azuaje FJ, Zhang L, Devaux Y, Wagner DR: Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Sci Rep. 2011, 1:
43.
Li S, Zhang B: Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013, 11 (2): 110-120.CrossRefPubMed
44.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13 (11): 2498-2504. 10.1101/gr.1239303.CrossRefPubMedPubMedCentral
45.
Archetti F, Lanzeni S, Messina E, Vanneschi L: Genetic Programming for Human Oral Bioavailability of Drugs. Proceedings of the 8th Annual Conference on Genetic and Evolutionary Computation. 2006, ACM, 255-262.
46.
Di L, Kerns E: Profiling drug-like properties in discovery research. Curr Opin Chem Biol. 2003, 7 (3): 402-408. 10.1016/S1367-5931(03)00055-3.CrossRefPubMed
47.
Shang X, Pan H, Li M, Miao X, Ding H: Lonicera japonica Thunb.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2011, 138 (1): 1-21. 10.1016/j.jep.2011.08.016.CrossRefPubMed
48.
Chen C, Zhou J, Ji C: Quercetin: a potential drug to reverse multidrug resistance. Life Sci. 2010, 87 (11–12): 333-338.CrossRefPubMed
49.
Lin Y, Shi R, Wang X, Shen H-M: Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets. 2008, 8 (7): 634-646. 10.2174/156800908786241050.CrossRefPubMedPubMedCentral
50.
Rahden-Staron I, Czeczot H, Szumilo M: Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin. Mutat Res. 2001, 498 (1–2): 57-66.CrossRefPubMed
51.
Choi J, Piao Y, Kang K: Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res. 2011, 34 (4): 607-613. 10.1007/s12272-011-0411-x.CrossRefPubMed
52.
Ding Y, Zhang T, Tao J, Zhang L, Shi J, Ji G: Potential hepatotoxicity of geniposide, the major iridoid glycoside in dried ripe fruits of Gardenia jasminoides (Zhi-zi). Nat Prod Res. 2013, 27: 929-933. 10.1080/14786419.2012.673604.CrossRefPubMed
53.
Tang H, Min G, Ge B, Li Y, Liu X, Jiang S: Evaluation of protective effects of Chi-Zhi-Huang decoction on phase I drug metabolism of liver injured rats by cocktail probe drugs. J Ethnopharmacol. 2008, 117 (3): 420-426. 10.1016/j.jep.2008.02.020.CrossRefPubMed
54.
Chula S, Hang L, Yinying B, Jianning S, Shi R: The effects of notoginsenoside R (1) on the intestinal absorption of geniposide by the everted rat gut sac model. J Ethnopharmacol. 2012, 142 (1): 136-143. 10.1016/j.jep.2012.04.027.CrossRefPubMed
55.
Jang G, Harris R, Lau D: Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev. 2001, 21 (5): 382-396. 10.1002/med.1015.CrossRefPubMed
56.
Stoner C, Gifford E, Stankovic C, Lepsy C, Brodfuehrer J, Prasad J, Surendran N: Implementation of an ADME enabling selection and visualization tool for drug discovery. J Pharm Sci. 2004, 93 (5): 1131-1141. 10.1002/jps.20020.CrossRefPubMed
57.
Boran AD, Iyengar R: Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010, 13 (3): 297-309.PubMedPubMedCentral
58.
Boots A, Haenen G, Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008, 585 (2–3): 325-337.CrossRefPubMed
59.
Spinella M: The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev. 2002, 7 (2): 130-137.PubMed
60.
Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, Miyagi Y, Yasumitsu H, Miyazaki K: Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol. 1998, 153937–944 (3): 937-CrossRef
61.
Taubenberger JK, Morens DM: The pathology of influenza virus infections. Annu Rev Pathol. 2008, 3: 499-522. 10.1146/annurev.pathmechdis.3.121806.154316.CrossRefPubMedPubMedCentral
62.
Qiucheng L: The present state and prospect of the study of syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1998, 4 (4): 242-246.
63.
Albert D, Zündorf I, Dingermann T, Müller W, Steinhilber D, Werz O: Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002, 64 (12): 1767-1775. 10.1016/S0006-2952(02)01387-4.CrossRefPubMed
64.
McMillan R: Leukotrienes in respiratory disease. Paediatr Respir Rev. 2001, 2 (3): 238-244. 10.1053/prrv.2001.0146.PubMed
65.
Wang X, Xu X, Li Y, Li X, Tao W, Li B, Wang Y, Yang L: Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr Biol (Camb). 2012, 5: 351-371.CrossRef
66.
Ehrhardt C, Ludwig S: A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol. 2009, 11 (6): 863-871. 10.1111/j.1462-5822.2009.01309.x.CrossRefPubMed
67.
Fritz J, Ferrero R, Philpott D, Girardin S: Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006, 7 (12): 1250-1257. 10.1038/ni1412.CrossRefPubMed
68.
Chen G, Shaw M, Kim Y, Nuñez G: NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009, 4: 365-398. 10.1146/annurev.pathol.4.110807.092239.CrossRefPubMed
69.
Dinarello C: Biologic basis for interleukin-1 in disease. Blood. 1996, 87 (6): 2095-2147.PubMed
70.
Beg A: Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002, 23 (11): 509-512. 10.1016/S1471-4906(02)02317-7.CrossRefPubMed
71.
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001, 2 (8): 675-680. 10.1038/90609.CrossRefPubMed
72.
Fedson D: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses. 2009, 3 (4): 129-142. 10.1111/j.1750-2659.2009.00090.x.CrossRef
73.
Pang IK, Iwasaki A: Inflammasomes as mediators of immunity against influenza virus. Trends Immunol. 2011, 32 (1): 34-41. 10.1016/j.it.2010.11.004.CrossRefPubMed
74.
Romeo GR, Lee J, Shoelson SE: Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012, 32 (8): 1771-1776. 10.1161/ATVBAHA.111.241869.CrossRefPubMedPubMedCentral
75.
Hsu HY, Wen MH: Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem. 2002, 277 (25): 22131-22139. 10.1074/jbc.M111883200.CrossRefPubMed
76.
77.
Pasparakis M: Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009, 9 (11): 778-788. 10.1038/nri2655.CrossRefPubMed
78.
Mancino A, Lawrence T: Nuclear factor-kappaB and tumor-associated macrophages. Clin Cancer Res. 2010, 16 (3): 784-789. 10.1158/1078-0432.CCR-09-1015.CrossRefPubMed
Metadata
Title
A novel systems pharmacology model for herbal medicine injection: a case using reduning injection
Authors
Haixing Yang
Wenjuan Zhang
Chao Huang
Wei Zhou
Yao Yao
Zhenzhong Wang
Yan Li
Wei Xiao
Yonghua Wang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-14-430

Other articles of this Issue 1/2014

BMC Complementary Medicine and Therapies 1/2014 Go to the issue

Research article

Differentiating intraprofessional attitudes toward paradigms in health care delivery among chiropractic factions: results from a randomly sampled survey

Research article

Protective effect of Danggui (Radix Angelicae Sinensis) on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells

Research article

What is traditional acupuncture - exploring goals and processes of treatment in the context of women with early breast cancer

Research article

A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults

Research article

Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action

Research article

The quality of reports of randomized clinical trials on traditional Chinese medicine treatments: a systematic review of articles indexed in the China National Knowledge Infrastructure database from 2005 to 2012